Back to search

Article

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) In Paediatric Severe Allergic Asthma – A Romanian Perspective

2021-10-11

Abstract excerpt

<h4>Background: </h4> Asthma is the most common chronic disease affecting children and altering their quality of life. The severity of asthma is often modulated by immunoglobulin E (IgE)-mediated allergen sensitization and is associated with comorbid allergic dis-eases. Omalizumab is a humanized monoclonal antibody anti-IgE, the first biological therapy approved to treat patients aged &ge;6 years with severe aller...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f85afab3-abb0-58a8-8fe8-d7387a769774
DOI
10.20944/preprints202110.0160.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) In Paediatric Severe Allergic Asthma – A Romanian PerspectiveDOI 10.20944/preprints202110.0160.v1
Select a neighboring publication to make it the new centre.